American Pacific shows first glimpse of dual-commodity viability
Having acquired a highly sought-after asset in California earlier this year, American Pacific (ASX:ABR) has begun proving up its acquisition through early sampling and testworks at its Fort Cady Project — with a near-term Feasibility Study target of mid-2018 already set.
ABR is seeking to develop a dual-commodity project in California, producing boric acid and lithium in both commercial grades and quantities, according to early test results published today.
A total of five hydrochloric acid leach tests were performed on a five kilogram representative sample of core containing 6.2% B2O3 (11% H3BO3) and 505 ppm lithium. The tests lasted six hours and used different temperatures and different acid amounts to test recoveries of both lithium and boron. The first test used a 50°C fluid and maintained a pH of 0.5 for a period of six hours; generating 98.5% boron and 48.3% lithium recovery.
The 505ppm lithium is particularly significant when compared to other lithium brine producers such as SQM and Pure Energy, who are typically able to generate around 100-200ppm in each their respective Projects.
Test results in full:
Fort Cady current program hole locations and status as below:
Positive metallurgical results at an early stage improve the likelihood of ABR developing an economically viable Project, able to beat its nearest peers on cost, grade and quantity in boric acid. ABR wants to go one better by supplementing its known boric acid asset with a workable lithium-brine project.
It should be noted here that ABR is still in its early stages here and investors should seek professional financial advice if considering this stock for their portfolio.
As part of its lithium processing research and development, ABR has appointed The Saskatchewan Research Council (SRC) to complete a colemanite ore leaching test program for ABR’s Fort Cady Project. The purpose of the testing program was to investigate lithium extraction potential by HCl leach at various conditions.
A total of five HCl acid leach tests were performed on ABR’s composite sample at various conditions, with averages charted below.
It would seem ABR is keen to make early progress at Fort Cady, with strong margins a clear early target. “The excellent boron recoveries are particularly pleasing given we believe we are first and foremost a compelling boric acid project with a low capex target and likely high margins. Our lithium by-product project also looks compelling”, says ABR Managing Director & CEO Michael Schlumpberger.
“The addition of lithium enriched brines into the make-up solution should only increase our lithium by-product production. The initial testworks have helped inform our pilot plant test program that we expect to commence early in the new year.”
Given ABR’s swift ASX-listing and subsequent progress as a small-cap company, Finfeed.com reached out to ABR Executive Director Anthony Hall for an exclusive interview, to be published later this week.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.